Lewis Gryziewicz is an accomplished regulatory leader with over 30 years of experience in the pharmaceutical industry. Lew joined AnaptysBio in 2019 after having lead teams at Allergan, Johnson & Johnson, as well as biotech’s such as Acadia and Quark. He has extensive global expertise with small molecule and biologic development. He has been involved in all stages of development from pre-IND/ pre-CTA through phase 1,2,3 development, NDA, MAA, NDS submission and approval and support of marketed products. Lew lead the teams responsible for global approvals of OZURDEX, ACUVAIL ZYMAXID, LUMIGAN, COMBIGAN and ALPHAGAN. Lew holds degrees from University of Colorado (PHD), Fairleigh Dickinson University (MBA), Philadelphia College of Pharmacy and Science (BS), as well as many industry designations.